Inspire Investing LLC Acquires New Shares in LivaNova PLC $LIVN

Inspire Investing LLC acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the first quarter, HoldingsChannel.com reports. The firm acquired 25,597 shares of the company’s stock, valued at approximately $1,627,000.

Other large investors have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System bought a new stake in LivaNova in the first quarter valued at $1,004,000. SG Americas Securities LLC increased its holdings in shares of LivaNova by 256.6% in the 1st quarter. SG Americas Securities LLC now owns 86,490 shares of the company’s stock worth $5,497,000 after acquiring an additional 62,233 shares during the period. Diversified Trust Co increased its holdings in shares of LivaNova by 12.3% in the 1st quarter. Diversified Trust Co now owns 21,028 shares of the company’s stock worth $1,337,000 after acquiring an additional 2,303 shares during the period. Hsbc Holdings PLC lifted its position in LivaNova by 260.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,301 shares of the company’s stock valued at $1,255,000 after purchasing an additional 14,671 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new position in LivaNova during the 4th quarter valued at about $302,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several recent analyst reports. Robert W. Baird decreased their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. KeyCorp lifted their price target on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Barclays increased their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Mizuho raised their target price on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, LivaNova currently has a consensus rating of “Moderate Buy” and an average target price of $80.75.

LivaNova Stock Performance

LIVN stock opened at $82.24 on Wednesday. The company has a 50-day simple moving average of $72.87 and a 200 day simple moving average of $67.23. The company has a market capitalization of $4.52 billion, a P/E ratio of 42.18 and a beta of 0.88. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. LivaNova PLC has a fifty-two week low of $41.01 and a fifty-two week high of $83.98.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter last year, the company earned $0.88 EPS. LivaNova’s quarterly revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Sell-side analysts predict that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.35% of the stock is owned by company insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.